Status:
NOT_YET_RECRUITING
Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Chemotherapy Combined With Immunotherapy
Lead Sponsor:
Fudan University
Conditions:
Esophageal Adenocarcinoma
Radiotherapy
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Brief Summary The goal of this single-arm Phase II clinical trial is to learn whether low-dose radiotherapy (LDRT) can restore sensitivity to immunotherapy and prolong disease control in adults with ...
Eligibility Criteria
Inclusion
- Age≥18 years old;
- ECOG score 0-1;
- Histologically or cytologically confirmed esophageal squamous cell carcinoma that is locally advanced (unresectable) or metastatic (AJCC/TNM 8th edition).
- Progression during or after one prior systemic first-line regimen that contained both a platinum-based chemotherapy and a PD-1/PD-L1 inhibitor (progression must be documented radiologically or clinically). Patients who received neoadjuvant/adjuvant therapy containing a PD-1/PD-L1 inhibitor are considered first-line failures if progression/recurrence occurs during or within 6 months after completion of that therapy.
- At least one measurable lesion per RECIST 1.1 within 4 weeks before enrollment. NOTE: a previously irradiated lesion cannot serve as a target lesion unless clear progression after radiotherapy is documented.
- Life expectancy ≥ 3 months.
- Adequate organ function within 1 week before enrollment:
- Hematologic: Hb ≥ 80 g/L; WBC ≥ 3.0 × 10⁹/L or ANC ≥ 1.5 × 10⁹/L; platelets ≥ 100 × 10⁹/L.
- Hepatic: total bilirubin ≤ 1.5 × ULN (direct bilirubin ≤ ULN if total \> 1.5 × ULN); ALT/AST ≤ 2.5 × ULN.
- Renal: serum creatinine \< 1.5 × ULN or creatinine clearance ≥ 50 mL/min; BUN ≤ 200 mg/L; albumin ≥ 30 g/L.
- Ability to understand and provide written informed consent.
Exclusion
- Active autoimmune disease (e.g., inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, vasculitis).
- Symptomatic interstitial lung disease or active infectious/non-infectious pneumonitis.
- Tumor invasion into adjacent organs (aorta or trachea) with high risk of bleeding or fistula; prior esophageal stent placement.
- Other malignancies within the past 2 years (except adequately treated basal-cell carcinoma, cervical carcinoma in situ, etc.).
- Active infection, heart failure, myocardial infarction within 6 months, unstable angina, or uncontrolled arrhythmia.
- Any condition that, in the investigator's opinion, could interfere with study results or increase patient risk.
- Mixed small-cell histology.
- Pregnant or breastfeeding women.
- Congenital or acquired immunodeficiency, HIV infection, prior organ or allogeneic stem-cell transplantation.
- Active HBV, HCV, or tuberculosis infection.
- Prior tumor vaccine or any live vaccine within 4 weeks (inactivated influenza vaccine is allowed).
- Concurrent use of other immunosuppressive agents, chemotherapy, investigational drugs, or chronic corticosteroids.
- Psychiatric illness, substance abuse, or social issues that could compromise compliance.
- Prior intolerance, hypersensitivity, or contraindication to PD-1/PD-L1 inhibitors or chemotherapy components.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2027
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT07164690
Start Date
September 1 2025
End Date
July 1 2027
Last Update
September 10 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.